InvestorsHub Logo
Followers 9
Posts 540
Boards Moderated 0
Alias Born 01/26/2014

Re: oldsport post# 1784

Monday, 02/02/2015 8:22:19 AM

Monday, February 02, 2015 8:22:19 AM

Post# of 3839
My understanding is that GALT is supplying the drug only for the melanoma trials. If those trials follow the pre clinical findings I'll bet that Merck will be putting in a big bid to buy.

It's fairly quick trial time too for keytruda and yervoy are already approved and in use. What would our value be if GR-MD-02 were approved as an additive therapy for most types of cancers?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News